ClinicalTrials.gg
RecruitingNCT03831997Updated Nov 6, 2026

Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence

An observational study in Chronic Subdural Hematoma, sponsored by Carilion Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Carilion Clinic · Observational

How we know

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 10 months later.
Updated Nov 6, 2026Now RecruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
35
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Hematoma, Subdural, Chronic with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Hematoma, Subdural, Chronic · United States.

Started
2019
with 2 others
Observational
7 of 22
5 open now
Registered
3rd of 22
by date
Lead sponsor
2 of 22
Carilion Clinic

Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, this one is one of 3 that started in 2019, is one of 7 observational ones, and was the 3rd registered.

Hematoma, Subdural, Chronic

113 studies on the registry are indexed under Hematoma, Subdural, Chronic; 50 are open to participants now.

Browse Hematoma, Subdural, Chronic studies →

Open to participants now

10 of the 22 studies in Hematoma, Subdural, Chronic with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hematoma, Subdural, Chronic studies recruiting now, 26 (72%) set no upper age limit and 1 (3%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Hematoma, Subdural, Chronic with a site in United States, or all of them as a file.
02

Study summary

This study aims to reduce the recurrence rate of chronic subdural hematomas (CSDH) by manipulating the post-operative intravenous fluid use. The hypothesis relies on the relationship between osmolality and volume changes related to osmolality. We will be administering dextrose 5% in 1/4 normal saline (D5 1/4NS) post-operatively to induce brain expansion which can take up the residual CSDH space, to help reduce recurrence rate.

Read the detailed description

Chronic subdural hematoma (CSDH) is a neurological disease characterized by a collection of fluid, blood, and blood degradation matter between the arachnoid and dura mater in a well-developed membrane cavity. The presentation of this disease begins with minor head trauma and takes 4-7 weeks to become symptomatic.

One of the significant problems exists with CSDH is the rate of recurrence, which currently stands at a 7-30% rate worldwide. The recurrence of a CSDH is typically defined as the presence of residual or recurrent CSDH after the first resolution, leading to additional surgical intervention either within 3 months (early recurrence) or after 3 months (late recurrence). Additional surgical intervention (recurrence rate) is the outcome variable that our study will be looking at. Factors leading to persistent recurrence include age, use of anticoagulant therapy, volume of hematoma cavity, degree of midline shift on CT, presence of residual air post-operatively, and volume of residual hematoma fluid. The variability in surgeons' operative and post-operative care, which tries to address the multiple factors that lead to recurrence, illustrates the difficulty in trying to reduce postoperative recurrence. In fact, there is no postoperative standard of care. These variations in operative and postoperative care have yet to significantly decrease the recurrent rate of CSDH.

Given the health status and fragility of the patient population that is most commonly affected by CSDHs, and the inherent morbidity related to operating on this population, we hypothesize that D5 1/4NS can help mitigate the issue of residual/recurrence CSDH leading to subsequent surgeries. The fluid dynamics of D5 1/4NS have been studied and we can assume that it will facilitate brain re-expansion.

03

Conditions studied

  • Chronic Subdural Hematoma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

We will be recruiting patients (male, female; 18-60 years old) from our center, Carilion Roanoke Memorial Hospital, that have been diagnosed with CSDH necessitating burr-hole evacuation who fit our inclusion and exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of chronic subdural hematoma (based on imaging)
  • Need for surgical intervention (assessed by attending neurosurgeon based on full neurological assessment)
  • The procedure of choice is burr hole drainage
  • Cessation of anti-coagulant therapy with accompanying normal lab values in appropriate time frames respective to the drug
  • Tolerance of supine position

Exclusion criteria

Exclusion Criteria:

  • \<60 years old
  • Presence of acute hemorrhage, stroke, or parenchymal damage
  • Neurological deficits not accountable to mass effect
  • Hyponatremia or inherent electrolyte imbalances
  • Pregnancy or non-consentable patients
  • Previous neurological surgery up to 1 year before being considered for the study
  • Rapid re-expansion of brain observed intraoperatively by attending neurosurgeon
  • Congestive heart failure or other medical conditions precluding normal postoperative administration of IV fluids
  • Blood glucose levels > 135 mg/dL
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
35 participants (estimated)
Patient registry
No

Groups and cohorts

  • Historical Controls

    The retrospective arm will consist of our control group, it will be derived from a retrospective medical chart review of all patients with CSDH at the facility.

  • Prospective Arm

    The prospective arm of the study will be looking at the effects of Dextrose 5% W/ Sodium Chloride 0.225% on the recurrence rate defined by the need for secondary surgical intervention for residual/recurrent CSDH) of CSDH in a 3-month post-operative window.

    Drug: Dextrose 5% W/ Sodium Chloride 0.225%

Interventions

  • DrugDextrose 5% W/ Sodium Chloride 0.225%

    Drug page: GlucoseStudies of GlucoseGlucose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    D5 1/4NS is comprised of 5% dextrose in a 0.225% sodium chloride (NaCl) solution. D5 1/4NS is initially slightly hypertonic to plasma, with an osmolarity of 321 mOSm/L. As the glucose component is rapidly metabolized, 0.225% NaCl solution remains and is hypotonic to plasma at an osmolarity of 77 mOsm/L. Because of the hypotonicity of the 1/4NS, it shifts into the intracellular compartments, followed by free water, and allows for volume expansion.

    Also known as: D5 1/4NS

06

What researchers measure

Primary outcomes

  1. Recurrence Rate

    We will see how many patients who are treated with D5 1/4NS have a recurrent episode of CSDH after their post-operative treatment.

    Time frame: Within 120 days (+/- 7 days) of their initial burr-hole surgery.

Secondary outcomes

  1. Rate of Volume Change of Residual CSDH Space

    We will see how fast the brain volume expands after the administration of both NS and D5 1/4NS.

    Time frame: 24 (+/- 6 hours) hours post-operative.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Alvis-Miranda HR, Castellar-Leones SM, Moscote-Salazar LR. Intravenous Fluid Therapy in Traumatic Brain Injury and Decompressive Craniectomy. Bull Emerg Trauma. 2014 Jan;2(1):3-14. PubMed 27162857 ↗
  • Balser D, Farooq S, Mehmood T, Reyes M, Samadani U. Actual and projected incidence rates for chronic subdural hematomas in United States Veterans Administration and civilian populations. J Neurosurg. 2015 Nov;123(5):1209-15. doi: 10.3171/2014.9.JNS141550. Epub 2015 Mar 20. PubMed 25794342 ↗
  • De Bonis P, Trevisi G, de Waure C, Sferrazza A, Volpe M, Pompucci A, Anile C, Mangiola A. Antiplatelet/anticoagulant agents and chronic subdural hematoma in the elderly. PLoS One. 2013 Jul 12;8(7):e68732. doi: 10.1371/journal.pone.0068732. Print 2013. PubMed 23874740 ↗
  • Dickerson RN, Maish GO 3rd, Weinberg JA, Croce MA, Minard G, Brown RO. Safety and efficacy of intravenous hypotonic 0.225% sodium chloride infusion for the treatment of hypernatremia in critically ill patients. Nutr Clin Pract. 2013 Jun;28(3):400-8. doi: 10.1177/0884533613483840. Epub 2013 Apr 22. PubMed 23609478 ↗
  • Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KLH, Hutchinson PJ. Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy. J Neuroinflammation. 2017 May 30;14(1):108. doi: 10.1186/s12974-017-0881-y. PubMed 28558815 ↗
  • Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, Bauer C, Jennings D, Fennessy F, Sonka M, Buatti J, Aylward S, Miller JV, Pieper S, Kikinis R. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012 Nov;30(9):1323-41. doi: 10.1016/j.mri.2012.05.001. Epub 2012 Jul 6. PubMed 22770690 ↗
  • Feldman Z, Kanter MJ, Robertson CS, Contant CF, Hayes C, Sheinberg MA, Villareal CA, Narayan RK, Grossman RG. Effect of head elevation on intracranial pressure, cerebral perfusion pressure, and cerebral blood flow in head-injured patients. J Neurosurg. 1992 Feb;76(2):207-11. doi: 10.3171/jns.1992.76.2.0207. PubMed 1730949 ↗
  • Janowski M, Kunert P. Intravenous fluid administration may improve post-operative course of patients with chronic subdural hematoma: a retrospective study. PLoS One. 2012;7(4):e35634. doi: 10.1371/journal.pone.0035634. Epub 2012 Apr 20. PubMed 22532865 ↗
  • Kirk T, Jones K, Miller S, Corbett J. Measurement of intraocular and intracranial pressure: is there a relationship? Ann Neurol. 2011 Aug;70(2):323-6. doi: 10.1002/ana.22414. Epub 2011 Jun 27. PubMed 21710618 ↗
  • Komotar RJ, Starke RM, Connolly ES. The role of drain placement following chronic subdural hematoma evacuation. Neurosurgery. 2010 Feb;66(2):N15-6. doi: 10.1227/01.neu.0000367840.82764.3a. No abstract available. PubMed 20087120 ↗
  • Matsumoto H, Hanayama H, Okada T, Sakurai Y, Minami H, Masuda A, Tominaga S, Miyaji K, Yamaura I, Yoshida Y. Which surgical procedure is effective for refractory chronic subdural hematoma? Analysis of our surgical procedures and literature review. J Clin Neurosci. 2018 Mar;49:40-47. doi: 10.1016/j.jocn.2017.11.009. Epub 2017 Dec 20. PubMed 29274740 ↗
  • Montano N, Stifano V, Skrap B, Mazzucchi E. Management of residual subdural hematoma after burr-hole evacuation. The role of fluid therapy and review of the literature. J Clin Neurosci. 2017 Dec;46:26-29. doi: 10.1016/j.jocn.2017.08.041. Epub 2017 Sep 5. PubMed 28887078 ↗
  • Motiei-Langroudi R, Stippler M, Shi S, Adeeb N, Gupta R, Griessenauer CJ, Papavassiliou E, Kasper EM, Arle J, Alterman RL, Ogilvy CS, Thomas AJ. Factors predicting reoperation of chronic subdural hematoma following primary surgical evacuation. J Neurosurg. 2018 Nov 1;129(5):1143-1150. doi: 10.3171/2017.6.JNS17130. Epub 2017 Dec 15. PubMed 29243977 ↗
  • Oh HJ, Lee KS, Shim JJ, Yoon SM, Yun IG, Bae HG. Postoperative course and recurrence of chronic subdural hematoma. J Korean Neurosurg Soc. 2010 Dec;48(6):518-23. doi: 10.3340/jkns.2010.48.6.518. Epub 2010 Dec 31. PubMed 21430978 ↗
  • Prud'homme M, Mathieu F, Marcotte N, Cottin S. A Pilot Placebo Controlled Randomized Trial of Dexamethasone for Chronic Subdural Hematoma. Can J Neurol Sci. 2016 Mar;43(2):284-90. doi: 10.1017/cjn.2015.393. Epub 2016 Feb 8. PubMed 26853325 ↗
  • Rohde V, Graf G, Hassler W. Complications of burr-hole craniostomy and closed-system drainage for chronic subdural hematomas: a retrospective analysis of 376 patients. Neurosurg Rev. 2002 Mar;25(1-2):89-94. doi: 10.1007/s101430100182. PubMed 11954771 ↗
  • Thotakura AK, Marabathina NR. Nonsurgical Treatment of Chronic Subdural Hematoma with Steroids. World Neurosurg. 2015 Dec;84(6):1968-72. doi: 10.1016/j.wneu.2015.08.044. Epub 2015 Sep 2. PubMed 26342776 ↗
  • Yadav YR, Parihar V, Namdev H, Bajaj J. Chronic subdural hematoma. Asian J Neurosurg. 2016 Oct-Dec;11(4):330-342. doi: 10.4103/1793-5482.145102. PubMed 27695533 ↗
  • Zhang Y, Chen S, Xiao Y, Tang W. Effects of Dexamethasone in the Treatment of Recurrent Chronic Subdural Hematoma. World Neurosurg. 2017 Sep;105:115-121. doi: 10.1016/j.wneu.2017.05.135. Epub 2017 May 31. PubMed 28578110 ↗
  • Zornow MH, Prough DS. Fluid management in patients with traumatic brain injury. New Horiz. 1995 Aug;3(3):488-98. PubMed 7496759 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2019 (actual). Primary completion is estimated for Jan 2030, 131 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jan 2022 → Jan 2030 and completion Jun 2022 → Jun 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2019
First posted
Feb 6, 2019
StartActual
Jan 17, 2019
Primary completionEst.
Jan 1, 2030was Jan 2022
CompletionEst.
Jun 1, 2030was Jun 2022
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Recruiting
changed Nov 6, 2026
Primary completion
Jan 1, 2022→Jan 1, 2030
Nov 6, 2026
Study completion
Jun 1, 2022→Jun 1, 2030
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Status unknown→Recruiting
    Primary completion Jan 1, 2022→Jan 1, 2030
    Study completion Jun 1, 2022→Jun 1, 2030
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03831997
Lead sponsor
Carilion Clinic
Responsible party
Eric A. Marvin (Principle Investigator, Carilion Clinic) — Principal investigator
First posted
Feb 6, 2019
Start date
Jan 17, 2019
Primary completion
Jan 1, 2030 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

Eric A Marvin, DO
Contact
eamarvin@carilionclinic.org
5405889711
Ayesha Kar, BS
Contact
akar@carilionclinic.org
9082080082
Eric Marvin, DO
principal investigator · Carilion Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion